noninvasive-diagnostics
(2)
Geneoscopy
Geneoscopy is a St. Louis life-sciences company building noninvasive diagnostics that read RNA biomarkers in stool to prevent, detect, and treat gastrointestinal disease. Its flagship product, ColoSense, is the first FDA-approved multi-target stool RNA (mt-sRNA) test for colorectal cancer screening in adults 45 and older, designed to lift screening compliance by replacing the colonoscopy prep and the clinic visit with a kit that arrives in the mail. Founded by siblings Andrew and Erica Barnell, the company is extending its RNA platform from cancer screening into inflammatory bowel disease.
Andrew Barnell
Andrew Barnell is the co-founder and CEO of Geneoscopy, a St. Louis life sciences company that turned a sibling conversation about a missed colonoscopy into ColoSense, the first FDA-approved stool RNA test for colorectal cancer screening. A Cornell economics graduate and Wharton MBA who started in J.P. Morgan's healthcare investment banking group and private equity at Lindsay Goldberg, Barnell paired his finance background with the scientific work of his sister and co-founder Erica Barnell, MD/PhD, to build a company that has raised more than $217 million and earned FDA approval for a noninvasive screening test built on patented RNA biomarker technology.